Sartorius Stedim Biotech provides earnings guidance for the full year 2022. The company expects Sales revenue to increase by 14% to 18% with sustained high profitability.
Real-time
Other stock markets
|
5-day change | 1st Jan Change | ||
158.2 EUR | +0.57% | -10.77% | -33.92% |
06-20 | Sartorius stabilizes after previous day's price slide | DP |
06-19 | Sartorius on the downswing again - low since 2020 is approaching | DP |
EPS Revisions
1st Jan change | Capi. | |
---|---|---|
-33.92% | 16.39B | |
-4.16% | 184B | |
-2.39% | 103B | |
-4.08% | 67.59B | |
+16.04% | 46.93B | |
-11.10% | 43.87B | |
+8.28% | 41.2B | |
+17.63% | 30.47B | |
-8.10% | 23.57B | |
+13.59% | 24.16B |
- Stock Market
- Equities
- DIM Stock
- News Sartorius Stedim Biotech
- Sartorius Stedim Biotech Provides Earnings Guidance for the Full Year 2022